for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

現在値

103.60EUR

変化

-0.12(-0.12%)

出来高

1,361,866

本日のレンジ

103.28

 - 

104.36

52週レンジ

80.95

 - 

106.66

∙ 約20分前の相場を表示しています。

適時開示

Ratings agency Fitch upgrades Sanofi's outlook to positive, keeps 'A+' long-term rating

May 23 (Reuters) - Sanofi SA <SASY.PA>::FITCH REVISES SANOFI'S OUTLOOK TO POSITIVE; AFFIRMS AT 'A+'.FITCH RATINGS HAS REVISED SANOFI S.A.'S OUTLOOK TO POSITIVE FROM STABLE, WHILE AFFIRMING ITS LONG-TERM ISSUER DEFAULT RATING (IDR) AT 'A+'..FITCH: COULD LOOK TO UPGRADE SANOFI RATINGS TO 'AA-' IF WE SEE SUCCESSFUL DEPLOYMENT OF INTERNAL RESEARCH AND DEVELOPMENT INVESTMENTS AND BOLT-ON ACQUISITIONS.

Sanofi: CHMP Recommends Approval Of ASMD Treatment Xenpozyme

May 20 (Reuters) - Sanofi SA <SASY.PA>::CHMP RECOMMENDS APPROVAL OF XENPOZYME® (OLIPUDASE ALFA), FIRST AND ONLY TREATMENT FOR ASMD.RECOMMENDATION BASED ON POSITIVE RESULTS FROM TWO CLINICAL TRIALS IN WHICH XENPOZYME PROVIDED IMPROVEMENT ACROSS MULTIPLE NON-CNS CLINICAL MANIFESTATIONS OF ASMD IN PEDIATRIC AND ADULT PATIENTS.ASMD IS A RARE, PROGRESSIVE, AND POTENTIALLY LIFE-THREATENING DISEASE WITH NO APPROVED TREATMENTS IN EUROPE.EUROPEAN COMMISSION WILL REVIEW CHMP RECOMMENDATION AND IS EXPECTED TO MAKE A FINAL DECISION IN COMING MONTHS.

Sanofi: positive data for Sarclisa® (isatuximab) and oncology pipeline

May 17 (Reuters) - Sanofi SA <SASY.PA>::NEW RESEARCH AT 2022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY UNDERSCORES SANOFI'S COMMITMENT TO IMPROVING CARE ACROSS ITS CORE FOCUS AREAS, INCLUDING MULTIPLE MYELOMA, LUNG AND BREAST CANCERS..EARLY CLINICAL DATA FOR SARCLISA® (ISATUXIMAB) SUBCUTANEOUS ADMINISTRATION USING AN ON-BODY DELIVERY DEVICE HIGHLIGHT POTENTIAL FOR A UNIQUE, PATIENT-CENTRIC TREATMENT EXPERIENCE IN MULTIPLE MYELOMA.SAFETY AND EFFICACY DATA FOR OUR INVESTIGATIONAL ANTIBODY DRUG CONJUGATE (ADC) TUSAMITAMAB RAVTANSINE ADD TO GROWING BODY OF EVIDENCE FOR OUR POTENTIAL FIRST-IN-CLASS THERAPY FOR TREATMENT OF NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSQ NSCLC) WITH CEACAM5 EXPRESSION.Further company coverage: <SASY.PA>. (Reporting by Sudip Kar-Gupta). ((sudip.kargupta@thomsonreuters.com;)).

BRIEF-Sanofi Gives Update On Isatuximab Phase-3 Trial

Fixes headline:May 15 (Reuters) - Sanofi SA <SASY.PA>:.SARCLISA® (ISATUXIMAB) COMBINATION PROVIDES UNPRECEDENTED MEDIAN PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA RECEIVING A PROTEASOME INHIBITOR THERAPY.LATEST RESULTS OF PHASE 3 IKEMA TRIAL DEMONSTRATE LONGEST MEDIAN PROGRESSION FREE SURVIVAL (MPFS) ON A PROTEASOME INHIBITOR BACKBONE IN PATIENTS WHO RELAPSED AFTER A PRIOR THERAPY, INCLUDING LENALIDOMIDE.MEDIAN PROGRESSION FREE SURVIVAL, INCREASED FROM 19.2 MONTHS TO 35.7 MONTHS WHEN SARCLISA WAS ADDED TO CARFILZOMIB AND DEXAMETHASONE.RESULTS WILL BE DISCUSSED WITH REGULATORY AUTHORITIES AT A FUTURE DATE.Further company coverage: <SASY.PA>. ((Tassilo.Hummel@thomsonreuters.com; +33 (0) 6 75 31 92 00;)).

Sanofi: new nirsevimab data analyses reinforce efficacy against respiratory syncytial virus (RSV)

May 11 (Reuters) - Sanofi SA <SASY.PA>::REG-PRESS RELEASE: NEW NIRSEVIMAB DATA ANALYSES REINFORCE EFFICACY AGAINST RSV.NEW NIRSEVIMAB DATA ANALYSES REINFORCE EFFICACY AGAINST RSV.A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV).Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose.

Rallybio Announces In-Licensing Of Potential First-In-Class Preclinical Antibody Candidate From Sanofi

May 10 (Reuters) - Rallybio Corp <RLYB.O>::RALLYBIO ANNOUNCES IN-LICENSING OF POTENTIAL FIRST-IN-CLASS PRECLINICAL ANTIBODY CANDIDATE FROM SANOFI.RALLYBIO CORP - UNDER TERMS OF LICENSE AGREEMENT, CO WILL MAKE AN UPFRONT CASH PAYMENT OF $3 MILLION TO SANOFI.RALLYBIO - UNDER LICENSE AGREEMENT, CO WILL PAY DEVELOPMENT & COMMERCIAL MILESTONES, & MID TO HIGH SINGLE DIGIT ROYALTIES ON NET SALES TO SANOFI.

Healthcare company Sanofi launches new philanthropic endowment fund "Foundation S"

May 4 (Reuters) - Sanofi SA <SASY.PA>::REG-PRESS RELEASE: FOUNDATION S: SANOFI’S NEW PHILANTHROPIC SPEARHEAD.TODAY LAUNCHES FOUNDATION S - SANOFI COLLECTIVE, ITS PHILANTHROPIC ENDOWMENT FUND.Foundation S will incorporate as its cornerstone initiative the former Sanofi Espoir Foundation’s ‘My Child Matters’ program in childhood cancer. .FOUNDATION S WILL BEGIN BY COLLABORATING WITH INTERNATIONAL NGO FRIENDSHIP, BANGLADESH-BASED, FOCUSED ON THAT NATION'S HARD-TO-REACH, CLIMATE-VULNERABLE ISLANDS OF GAIBANDHA.To better help vulnerable populations, Foundation S will leverage Sanofi’s longstanding emergency aid expertise and improve the connection between humanitarian and development financing..

Euroapi Says All Conditions For Upcoming Listing Are Met

May 3 (Reuters) - EUROAPI::EUROAPI ANNOUNCES THAT ALL CONDITIONS REQUIRED FOR ITS UPCOMING LISTING ON EURONEXT PARIS HAVE NOW BEEN SUCCESSFULLY MET.THE DISTRIBUTION VIA AN ADDITIONAL EXTRAORDINARY DIVIDEND IN KIND OF CIRCA 58% OF EUROAPI SHARES TO SANOFI SHAREHOLDERS HAS BEEN APPROVED IN TODAY'S SANOFI ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING.Further company coverage: SASY.PA. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;)).

Sanofi To Distribute A Cash Dividend Of 3.33 Euros Per Share

May 3 (Reuters) - Sanofi SA <SASY.PA>::ANNUAL GENERAL MEETING OF MAY 3, 2022.DISTRIBUTION OF A CASH DIVIDEND OF EUR 3.33 PER SHARE AND A DIVIDEND IN KIND OF EUROAPI SHARES, AT A RATIO OF ONE (1) EUROAPI SHARE PER TWENTY-THREE (23) SANOFI SHARES, WITH PAYMENT AS OF MAY 10, 2022.BOARD COMPOSITION: RENEWALS AND APPOINTMENT OF THREE NEW INDEPENDENT DIRECTORS.PAYMENT OF DIVIDEND, INCLUDING BOTH CASH DIVIDEND AND DIVIDEND IN KIND, WILL BE MADE ON MAY 10, 2022.

Sanofi Q1 Business Operating Income Up At EUR 2.42 Billion

April 28 (Reuters) - SANOFI SA <SASY.PA>::Q1 IFRS NET SALES REPORTED EUR 9.67 BILLION +12.6% YOY.Q1 BUSINESS OPERATING INCOME EUR 3.07 BILLION +16.2% YOY.Q1 BUSINESS NET INCOME EUR 2.42 BILLION +20.2% YOY.Q1 BUSINESS EPS EUR 1.94, +20.5% YOY.CO DEVELOPPING WITH GSK NEXT-GENERATION BOOSTER COVID VACCINE DESIGNED TO PROVIDE BROAD PROTECTION AGAINST ALL VARIANTS OF CONCERN : DATA (VAT02 COHORT 2) IS EXPECTED TO BE COMMUNICATED IN Q2 2022.END-Q1 FREE CASH FLOW BEFORE RESTRUCTURING, ACQUISITIONS AND DISPOSALS DECREASED BY 15.5% TO EUR 1,998 MILLION.EXPECTS 2022 BUSINESS EPS TO GROW LOW DOUBLE-DIGIT AT CER, BARRING UNFORESEEN MAJOR ADVERSE EVENTS.APPLYING AVERAGE APRIL 2022 EXCHANGE RATES, POSITIVE CURRENCY IMPACT ON 2022 BUSINESS EPS IS ESTIMATED TO BE BETWEEN +4% TO +5%.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up